3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Multiple Myeloma
16
Burkitt Lymphoma
8
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Leukemia, Biphenotypic, Acute
3
Recurrence
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Lymphoma, Mantle-Cell
2
Lung Neoplasms
2
Immunoglobulin Light-chain Amyloidosis
2
Down Syndrome
2
Carcinoma, Non-Small-Cell Lung
2
Waldenstrom Macroglobulinemia
1
Uterine Cervical Neoplasms
1
Smoldering Multiple Myeloma
1
Rectal Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasm Metastasis
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell
1
Leukemia, Plasma Cell
1
Leukemia, Hairy Cell
1
Leukemia
1
Carcinoma
1
Brain Neoplasms
1
Anus Neoplasms
1
Ann Arbor Stage II Mantle Cell Lymphoma
1
Interventions
Cyclophosphamide
9
fludarabine
7
Dexamethasone
7
pomalidomide
6
Rituximab
6
pembrolizumab
5
selinexor
4
obinutuzumab
4
glofitamab
4
Lenalidomide
4
daratumumab
3
belantamab mafodotin
3
Temozolomide
3
Gemcitabine
3
Etoposide
3
Bortezomib
3
zanubrutinib
2
venetoclax
2
tocilizumab
2
fludarabine phosphate
2
enzalutamide
2
cemiplimab
2
carfilzomib
2
abemaciclib
2
PF06821497
2
Mesna
2
Lisaftoclax
2
Injections
2
Immunotherapy, Adoptive
2
Granulocyte Colony-Stimulating Factor
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recurrence
×
Calcium Dobesilate
×
30 days
×
Clear all
NCT05519085
2026-05-27
SUCCESSOR-1
Celgene
Phase 3
Recruiting
810 enrolled
NCT02343042
2026-05-04
STOMP
Karyopharm Therapeutics Inc
Phase 1/2
Active not recruiting
300 enrolled